SU-5402

Inhibits FGFR phosphorylation in vitro, in cell culture [1], and in mouse tumor cell models [2]. SU-5402 can suppress ECP induced cardiomyocyte differentiation of P19CL6 embryonic carcinoma cells via an FGFR3 dependent pathway [3].

References:

1) Lee et al. (2013), Interleukin-1β enhances cell migration through AP-κ1 and NF-B pathway dependent FGF2 expression in human corneal endothelial cells;  Biol. Cell, epub ahead of print Jan. 18 2013

2) Paterson et al. (2004), Preclinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myeloma;  Br. J. Haematol., 124 595

3) Jin et al. (2012), Eosinophil cationic protein enhances cardiomyocyte differentiation of P19CL6 embryonal carcinoma cells by stimulation the FGF receptor signaling pathway;  Growth Factors, 30 344